Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious ...
As generative AI continues to reshape the legal and corporate landscapes, actionable steps should now be at the forefront of crisis communication plans to help firms combat the rapid spread of ...